| Bioactivity | FTX-6746 is an orally active PPARG inhibitor. FTX-6746 shows potent tumor inhibition in mouse xenograft models[1]. |
| In Vivo | FTX-6746 (3-60 mg/kg；口服；每天 2 次，共 21 天) 在小鼠的 UMUC9 或 HT1197 异种移植模型中有显着的肿瘤抑制作用[1]。 Animal Model: |
| Name | FTX-6746 |
| CAS | 2829349-96-2 |
| Formula | C16H7ClF2N2O |
| Molar Mass | 316.69 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mertz J, et al. Novel inhibitors of the luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) durably eradicate tumors in urothelial cancer (UC) animal models[J]. European Journal of Cancer, 2022, 174: S33-S34. |